Risk of and duration of protection from SARS-CoV-2 reinfection assessed with real-world data

被引:8
|
作者
Reynolds, Shannon [1 ]
Kaufman, Harvey [2 ]
Meyer III, William [2 ]
Bush, Chris [1 ]
Cohen, Oren [3 ]
Cronin, Kathy [4 ]
Kabelac, Carly [1 ]
Leonard, Sandy [5 ]
Anderson, Steve [3 ]
Petkov, Valentina [4 ]
Lowy, Douglas [4 ]
Sharpless, Norman [4 ]
Penberthy, Lynne [4 ]
机构
[1] Aetion Inc, Sci & Delivery, New York, NY 10001 USA
[2] Quest Diagnost, Med Affairs, Secaucus, NJ USA
[3] Labcorp Drug Dev, Off Chief Med Off, Burlington, NC USA
[4] NCI, Div Canc Control & Populat Sci, Bethesda, MD USA
[5] HealthVer, Parternships & Real World Data, Philadelphia, PA USA
来源
PLOS ONE | 2023年 / 18卷 / 03期
关键词
INFECTION; ANTIBODIES;
D O I
10.1371/journal.pone.0280584
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
This retrospective observational study aimed to gain a better understanding of the protective duration of prior SARS-CoV-2 infection against reinfection. The objectives were two-fold: to assess the durability of immunity to SARS-CoV-2 reinfection among initially unvaccinated individuals with previous SARS-CoV-2 infection, and to evaluate the crude SARS-CoV-2 reinfection rate and associated risk factors. During the pandemic era time period from February 29, 2020, through April 30, 2021, 144,678,382 individuals with SARS-CoV-2 molecular diagnostic or antibody test results were studied. Rates of reinfection among index-positive individuals were compared to rates of infection among index-negative individuals. Factors associated with reinfection were evaluated using multivariable logistic regression. For both objectives, the outcome was a subsequent positive molecular diagnostic test result. Consistent with prior findings, the risk of reinfection among index-positive individuals was 87% lower than the risk of infection among index-negative individuals. The duration of protection against reinfection was stable over the median 5 months and up to 1-year follow-up interval. Factors associated with an increased reinfection risk included older age, comorbid immunologic conditions, and living in congregate care settings; healthcare workers had a decreased reinfection risk. This large US population-based study suggests that infection induced immunity is durable for variants circulating pre-Delta predominance.
引用
收藏
页数:17
相关论文
共 50 条
  • [21] Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2
    Chemaitelly, Hiam
    Ayoub, Houssein H.
    Tang, Patrick
    Hasan, Mohammad R.
    Coyle, Peter
    Yassine, Hadi M.
    Al-Khatib, Hebah A.
    Smatti, Maria K.
    Al-Kanaani, Zaina
    Al-Kuwari, Einas
    Jeremijenko, Andrew
    Kaleeckal, Anvar H.
    Latif, Ali N.
    Shaik, Riyazuddin M.
    Abdul-Rahim, Hanan F.
    Nasrallah, Gheyath K.
    Al-Kuwari, Mohamed G.
    Butt, Adeel A.
    Al-Romaihi, Hamad E.
    Al-Thani, Mohamed H.
    Al-Khal, Abdullatif
    Bertollini, Roberto
    Abu-Raddad, Laith J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (18): : 1716 - 1718
  • [22] Quantifying the risk of SARS-CoV-2 reinfection over time
    Murchu, Eamon O.
    Byrne, Paula
    Carty, Paul G.
    De Gascun, Cillian
    Keogan, Mary
    O'Neill, Michelle
    Harrington, Patricia
    Ryan, Mairin
    REVIEWS IN MEDICAL VIROLOGY, 2022, 32 (01)
  • [23] Real-world data on the incidence and risk of Guillain–Barré syndrome following SARS-CoV-2 vaccination: a prospective surveillance study
    Jongmok Ha
    Suyeon Park
    Hyunwook Kang
    Taeeun Kyung
    Namoh Kim
    Dong Kyu Kim
    Hyeonjoon Kim
    Kihoon Bae
    Min Cheol Song
    Kwang June Lee
    Euiho Lee
    Beom Seuk Hwang
    Jinyoung Youn
    Jin Myoung Seok
    Kunhee Park
    Scientific Reports, 13
  • [24] SARS-CoV-2 Vaccine Effectiveness in a High-Risk National Population in a Real-World Setting
    Butt, Adeel A.
    Omer, Saad B.
    Yan, Peng
    Shaikh, Obaid S.
    Mayr, Florian B.
    ANNALS OF INTERNAL MEDICINE, 2021, 174 (10) : 1404 - +
  • [25] Real-world performance of SARS-COV-2 serology tests in the United States
    Rodriguez-Watson, Carla V.
    Louder, Anthony
    Kabelac, Carly
    Frederick, Christopher
    Sheils, Natalie E.
    Eldridge, Elizabeth H.
    Lin, Nancy D.
    Gatz, Jennifer
    Grannis, Shaun J.
    Vashisht, Rohit
    Pollock, Benjamin
    Ghauri, Kanwal
    Knepper, Camille
    Leonard, Sandy
    Embi, Peter J.
    Jenkinson, Garrett
    Klesh, Reyna J.
    Patel, Ayan
    Dahm, Lisa
    Byington, Carrie L.
    Crews, Bridgit
    Butte, Atul J.
    Allen, Jeff
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 435 - 435
  • [26] SARS-CoV-2 reinfection: a case report from Portugal
    Fernandes, Ana Carolina
    Figueiredo, Rui
    REVISTA DA SOCIEDADE BRASILEIRA DE MEDICINA TROPICAL, 2021, 54
  • [27] Prior SARS-CoV-2 infection is associated with protection against symptomatic reinfection
    Hanrath, Aidan T.
    Payne, Brendan A. I.
    Duncan, Christopher J. A.
    JOURNAL OF INFECTION, 2021, 82 (04) : E29 - E30
  • [28] Reinfection with SARS-CoV-2: A case report from Libya
    Tekaa, Ibrahim A.
    BenHasana, Mohamed H.
    Alkershinia, Abdulsalam A.
    Alatresha, Omar K.
    Abulifaa, Tareg A.
    Lembaggaa, Hawa A.
    Alhudirid, Inas M.
    Elzagheidd, Adam
    TRAVEL MEDICINE AND INFECTIOUS DISEASE, 2021, 41
  • [29] Risk Factors Contributing to Reinfection by SARS-CoV-2: A Systematic Review
    Gomez-Gonzales, Walter
    Chihuantito-Abal, Luis A.
    Gamarra-Bustillos, Carlos
    Moron-Valenzuela, Julia
    Zavaleta-Oliver, Jenny
    Gomez-Livias, Maria
    Vargas-Pancorbo, Lidia
    Auqui-Canchari, Maria E.
    Mejia-Zambrano, Henry
    ADVANCES IN RESPIRATORY MEDICINE, 2023, 91 (06) : 560 - 570
  • [30] Reinfection With SARS-CoV-2: Implications for Vaccines
    Cohen, Jeffrey, I
    Burbelo, Peter D.
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (11) : E4223 - E4228